{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-227204","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2026-05-15T21:10:20+00:00","discovered_at":"2026-05-15T21:12:00.280767+00:00","generated_at":"2026-05-15T21:14:05.491545+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TuHURA Q1 cash $6.3M; secures $50M credit facility; IFx-2.0 gets ODD in melanoma","bullets":["Cash and equivalents $6.3M at March 31, 2026; net operating cash outflow $4.4M in Q1.","Established $50M credit facility with largest stockholder at 12% interest, maturing 2031; extends runway into 2028.","R&D expenses $5.2M (up from $4.6M YoY); G&A $2.3M (up from $2.0M YoY).","FDA Orphan Drug Designation granted for IFx-2.0 in stage IIB-IV melanoma.","Appointed Craig Tendler as CMO and Amanda Garofalo as SVP Clinical Operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-227204","json":"https://secwatch.observer/filing/0001193125-26-227204.json","markdown":"https://secwatch.observer/filing/0001193125-26-227204.md","text":"https://secwatch.observer/filing/0001193125-26-227204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/0001193125-26-227204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/hura-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:14:05.491545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e04c4b5df7bcc6698e729cc34d90d62d59b23cf4","claim":"TuHURA Biosciences, Inc./NV reported financial results for three months ended March 31, 2026.","evidence_excerpt":"Summary of Financial Results for the First Quarter 2026 Cash and cash equivalents of $6.3 million at March 31, 2026. TuHURA's total common shares outstanding were approximately 63.6 million. Research and development expenses were $5.2 million and $4.6 million for the 3 months ended March 31, 2026, and 2025, respectively. General and administrative (G&A) expenses were $2.3 million and $2.0 million for the 3 months ended March 31, 2026, and 2025, respectively. Net cash outflows from operating activities were ($4.4) million and ($4.7) million for the 3 months ended March 31, 2026, and 2025, respectively. Net cash flows from financing activities were $ 7.2 million and $ (0.5) million for the 3 months ended March 31, 2026, and 2025, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/0001193125-26-227204-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}